Why the study?
Prior studies showed that EEG spectral power ratio (SPR) was reduced in clinical AD and biomarker-confirmed aMCI, leading researchers to test whether cerebral slowing results from AD-associated pathology in cognitively unimpaired individuals using plasma Aβ42/Aβ40 levels.
Does high risk of brain amyloid associate with lower EEG spectral power ratio in cognitively unimpaired older adults?
Does high risk of brain amyloid associate with lower EEG spectral power ratio in cognitively unimpaired older adults?
The EEG spectral power ratio is a sensitive marker of preclinical Alzheimer's disease associated with amyloid pathology and executive function.
No takes yet. Share an insight, caveat, or question.
SPR reduction may mark AD-related slowing; leaves open diagnostic or monitoring utility pending validation.
Fried et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: